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Extracorporeal membrane oxygenation (ECMO) is a
mode of extracorporeal life support that augments
oxygenation, ventilation and/or cardiac output via
cannulae connected to a circuit that pumps blood
through an oxygenator and back into the patient.
ECMO has been used for decades to support
cardiopulmonary disease refractory to conventional
therapy. While not robust, there are promising data
for the use of ECMO in acute hypoxemic respiratory
failure, cardiac arrest, and cardiogenic shock and the
potential indications for ECMO continue to increase.
This review discusses the existing literature on the
potential use of ECMO in critically ill patients within
the emergency department.operating room. Several reports were published demon-Introduction
Extracorporeal life support (ECLS) is a general term used
to describe temporary support of cardiac or pulmonary
function using mechanical devices. When using the
“heart–lung machine” to completely bypass the cardiopul-
monary circulation, it is referred to as cardiopulmonary
bypass. When ECLS is used in the intensive care unit
(ICU) or emergency department (ED) to augment oxygen-
ation, ventilation, or cardiac output it is generally referred
to as extracorporeal membrane oxygenation (ECMO). As
the science of ECLS has progressed internationally, ECLS
use in United States ICUs has increased over 400 % since* Correspondence: jmosier@aemrc.arizona.edu
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(http://creativecommons.org/publicdomain/ze2006 [1]. This has led to interest in potential earlier appli-
cations in the ED, and possibly even the prehospital
setting. This review focuses on one modality of ECLS,
ECMO, and describes the history of ECMO, common
current applications, and important considerations related
to ECMO use in adult ED patients.
History
ECLS was initially developed in the 1950s by John Gibbon
as a means of oxygenating blood via a membrane oxy-
genator during prolonged operations on cardiopulmonary
bypass [2]. Given the lack of an open reservoir of blood
and extreme anticoagulation required with a traditional
cardiopulmonary bypass circuit, ECMO presented a less
complex and more sustainable option for treatment of re-
fractory cardiovascular and respiratory failure outside the
strating successful use in “shock-lung syndrome”, “adult
capillary leak syndromes”, and cardiopulmonary failure in
the late 1970s [3, 4]. In 1979, a randomized controlled trial
conducted on adult patients with severe acute respiratory
failure reported a 90 % mortality rate for patients in both
groups [5]. Thus, enthusiasm stalled and over the next
30 years ECMO was used mostly for neonatal and
pediatric patients with only a small number of highly spe-
cialized centers pursuing ECMO in adult patients.
Technological improvements and advances in other
aspects of critical care have created an ECMO landscape
that is very different from the early days of 90 % mortality.
For patients with severe hypoxemic respiratory failure, the
publication of the Conventional Ventilatory Support
versus Extracorporeal Membrane Oxygenation for Severe
Adult Respiratory Failure (CESAR) trial and several
reports of improved survival in patients with acute re-
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cant expansion of ECMO use [6–9]. Recent data show
promise when ECMO is used early in patients with car-
diac arrest to augment traditional cardiopulmonary resus-
citation in the form of extracorporeal cardiopulmonary
resuscitation (ECPR) [10–15]. ECPR may play a role in the
prehospital [16] or ED management of refractory cardiac
arrest, cardiovascular collapse due to pulmonary embol-
ism [17], hypothermia [18], drowning [19], overdoses [20],
airway obstruction [21], and severe electrolyte abnormal-
ities [22].
Current applications
Veno-venous ECMO for severe acute respiratory failure
Acute respiratory failure due to potentially reversible
processes such as ARDS or utilization as a bridge-to-
transplant have become the most common indications
for ECMO therapy in adults [23]. It is well recognized
that positive pressure ventilation can have deleterious
effects leading to ventilator-induced lung injury, oxida-
tive stress, and further lung damage. Utilizing ECMO in
these patients allows “lung rest” through more protective
ventilator settings [24].
Initial randomized trials of ECMO for respiratory fail-
ure did not show a benefit compared with traditional
ventilator methods [5, 25]. In the 1990s and 2000s, sur-
vival rates reported in case series with ECMO improved
to 52–75 % [26, 27]. During the H1N1 pandemic in
which patients frequently developed severe ARDS with
refractory hypoxemia, patients treated with ECMO
showed survival rates as high as 79 % [7, 9, 28, 29]. The
first modern randomized controlled trial of ECMO for
adult patients with ARDS, the CESAR trial, was published
in 2009. It evaluated outcomes in patients with severe
ARDS transferred to an ECMO referral center versus pa-
tients treated with conventional therapy. Although mortal-
ity at any point was not significantly different, the study
identified significantly higher 6-month survival rates in
the group transferred to the ECMO referral center—of
which only 75 % of the patients received ECMO—versus
the control group that were not transferred [30]. Thus, it
may have been other aspects of care at the ECMO center,
not necessarily the ECMO itself, that led to improved out-
comes. The Extracorporeal Membrane Oxygenation for
Severe Acute Respiratory Distress Syndrome (EOLIA) trial
is currently underway, evaluating early ECMO within
3 hours of initiation of mechanical ventilation for patients
with refractory hypoxemia and severe ARDS [31]. If this
trial finds a benefit of early ECMO for ARDS, coordinat-
ing transfer to ECMO-capable referral centers directly
from the ED for early initiation of ECMO support
may become important for patient outcomes [32]. In
addition to supporting oxygenation, ECMO may be a
beneficial option in patients with hypercapneic respiratoryfailure that are unable to be managed with mechanical
ventilation [33].
Veno-arterial ECPR for cardiac arrest
Despite advances in management, outcomes for both
in-hospital and out-of-hospital cardiac arrest remain
poor. In-hospital cardiac arrest treated with conven-
tional cardiopulmonary resuscitation (CPR) typically
has a survival rate of 15–17 % and out-of-hospital
cardiac arrest (OHCA) survival is even lower at only
8–10 % [34, 35]. The worst outcomes are in patients
with prolonged time to return of spontaneous circulation.
Prolonged cerebral hypoperfusion leads to significantly
worse neurologic sequelae and early initiation of ECPR
with veno-arterial (VA) ECMO may be a useful adjunct to
reducing the interval time from arrest to restoration of
cerebral perfusion.
Data for in-hospital arrest are the most promising,
likely due to the shorter interval from the onset of arrest
to initiation of ECMO flow. While there are no random-
ized trials to date, observational studies have reported an
association between ECPR and improved survival. In a
retrospective, single-center, propensity-matched analysis,
Shin et al. [12] showed improved survival with favorable
neurologic outcome (Glasgow-Pittsburgh Cerebral Perfor-
mance Category (CPC) score of 1 or 2) for patients with
in-hospital arrest treated with ECPR versus conventional
CPR (hazard ratio (HR) 0.17, 95 % confidence interval
(CI) 0.04–0.68). Chen et al. [11] found similar 30-day (HR
0.47, 95 % CI 0.28–0.77) and 1-year (HR 0.53, 95 % CI
0.33–0.83) survival for ECPR when compared with con-
ventional CPR. Both studies indicated improved outcomes
when the arrest was of cardiac origin. Another retrospect-
ive review of prolonged in-hospital arrests (>15 minutes)
or refractory shock after return of spontaneous circulation
showed nearly half of the patients who survived had a
CPC score of 1 or 2 with the use of ECPR [10]. Other ob-
servational studies have found variable improvements in
mortality with the use of ECPR [36, 37]. A recent meta-
analysis performed by Cardarelli et al. [38] in 135 patients
from 1990 to 2007 showed a hospital survival rate to dis-
charge with ECPR of 40 %.
Reports from OHCA studies are not as robust, al-
though there are dramatic reports of otherwise hopeless
cases rescued by ECMO [39]. Haneya et al. [40] com-
pared ECPR initiated in the ED for OHCA with ECPR
initiated for in-hospital cardiac arrest, and found a sur-
vival rate of 42 % for in-hospital arrest patients versus
only 15 % for OHCA patients. ECPR combined with
therapeutic hypothermia and intra-aortic balloon pump
placement was recently shown to improve neurologic
outcomes for OHCA patients with ventricular fibrillation
or pulseless ventricular tachycardia. This study demon-
strated survival with a favorable CPC score in 11.2 % of
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6 months [14]. Similar results were reported in a small
observational pilot study in Australia combining mech-
anical compression devices, ECPR, and hypothermia for
patients with refractory cardiac arrest. In this small
study, 5 of 11 OHCA patients and 9 of 15 in-hospital car-
diac arrest patients survived, and favorable neurological
outcome was achieved in half of the survivors [15].
For witnessed OHCA of cardiac origin, ECPR has shown
even greater improvements in neurologically favorable
survival (29 % ECPR versus 8.9 % CPR) [13]. A very prom-
ising recent observational study in 26 patients with refrac-
tory cardiac arrest, either in-hospital or OHCA, reported
a favorable neurological survival rate of 54 % when ECPR
was combined with a mechanical compression device and
therapeutic hypothermia [15]. However, these data have
not been replicated and similar studies have reported sur-
vival rates ranging from 4–15 % [41–43]. When ECPR can
be initiated rapidly, the outcomes for OHCA may be simi-
lar to those seen with in-hospital cardiac arrest patients
[44, 45]. Although there are no large prospective random-
ized trials and survival from refractory cardiac arrest is
poor, ECPR may provide a tool to improve survival with
good neurologic outcomes when initiated early in selected
patients.
While an optimistic estimate of survival from OHCA
with the use of ECPR may be in the 15–20 % range, the
critical factor that determines success appears to be the
duration from the onset of arrest to achieving ECMO
flow. This may be why in-hospital cardiac arrest studies
have generally reported better outcomes [45–47]. Further-
more, the volume of patients meeting optimal criteria for
ECPR, including witnessed ventricular fibrillation/tachy-
cardia with a short interval to initiation of CPR, refractory
arrest despite optimal resuscitative efforts, and <75 years
of age comprises a very small (<10 %) subset of all patients
with OHCA [48, 49]. Additionally, complication rates of
ECPR remain high [43, 50, 51]. Currently the American
Heart Association’s position is that evidence does not
support a recommendation for ECPR, although it may be
considered in highly specialized centers in patients who
have a potentially reversible disease and a short duration
of cardiac arrest [52]. The recent Institute of Medicine re-
port on cardiac arrest care states ECMO is an emerging
technology that has promise in improving cardiac arrest
care and should be developed and researched [53].
VA ECMO for shock
In addition to ECPR, ECMO may have a role in select
patients with cardiogenic or septic shock [54–56], toxic
ingestions [57], thyrotoxicosis [58], or trauma [59]. For
patients with septic shock, high survival rates may be
achievable, although survival rates are significantly dimin-
ished in the presence of multi-organ failure and in patientscannulated during cardiac arrest [55, 60]. ECMO has
shown promising results as a method of supporting
hemodynamics in patients with cardiogenic shock due to
acute myocardial infarction [61], massive pulmonary em-
bolism [62] or myocarditis [63]. ECMO may be preferable
to aortic balloon pumps as it can provide more robust
biventricular support by increasing right ventricular drain-
age in addition to supporting gas exchange, and it can be
employed quickly at the bedside. However, the downside
of ECMO for cardiac support is that because of the re-
trograde aortic flow, left ventricular afterload and oxygen
demand increase without the placement of a left ventricu-
lar drain. ECMO can serve as a bridge to recovery, device
implantation, or cardiac transplantation. Small trials have
shown improved survival rates in patients placed on
ECMO as a bridge to a left ventricular assist device and
subsequently to transplantation [64]. Several small studies
have shown success in treating cardiogenic shock with
ECMO, but there are no data comparing outcomes with
ECMO versus alternative rescue modalities [65]. Arran-
ging the initiation of ECMO may be a viable option in
patients with known severe cardiac dysfunction in shock
refractory to conventional therapy in the ED.
Important considerations
Programmatic considerations
A successful ECLS program requires a significant multi-
disciplinary and organizational commitment to ensure
necessary resources and personnel [66]. Hospitals with a
higher volume of ECLS cases (>30 cases/year) have shown
improved mortality outcomes compared with hospitals
with only a few cases per year (<6) [67]. Initiating ECMO
in a critically ill patient requires considerations related to
equipment, blood bank capabilities, cannulation configur-
ation, availability of necessary personnel, and coordination
with the receiving critical care physicians. In a recent trial
evaluating ECMO for OHCA, initiation of ECMO re-
quired two critical care physicians for cannulation, a third
physician providing ultrasound guidance of cannula place-
ment in the inferior vena cava, a fourth physician dedi-
cated to leading the resuscitation, a nurse coordinator to
initiate the circuit, and a sixth person to infuse cold saline
for intra-arrest hypothermia [15]. Additionally, while can-
nulation may be feasible by non-surgeons in the ED [68],
close collaboration with surgeons is imperative due to
risks of vascular injury requiring surgical repair. A suc-
cessful ECLS program requires physicians, nurses, perfu-
sionists, and respiratory therapists trained and competent
in cannulation and management of the ECLS circuit to be
available in sufficient numbers to provide 24/7 coverage.
A streamlined exit strategy from the ED should be estab-
lished, whether that includes transfer to the cardiac
catheterization lab, ICU, or transfer to an ECMO receiving
hospital. Predetermined inclusion and exclusion criteria,
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ECMO in a patient who fails to improve are important to
optimize outcomes and resource utilization. Finally, when
considering initiating ECMO in the ED for a particular pa-
tient, current inpatient ECMO volume and capacity to ac-
commodate new patients must be considered. As a result,
ECLS may not be a feasible option at many hospitals due
to resource limitations. Local, regional, and inter-regional
networks of hospitals with direct communication with the
ECMO referral center that provides a mobile rescue team
for cannulation and transport of patients with critical car-
diopulmonary failure may be the optimal solution to alle-
viate many of these costly programmatic considerations.
Technical considerations
Cannulation strategies must be carefully considered
based on the underlying pathophysiology. Configurations
include veno-venous (VV) and VA approaches, with hy-
brid modes possible for specialized uses (e.g., veno-
arterial-venous for patients with cardiogenic shock and
differential hypoxemia). In VV ECMO, patients are typ-
ically cannulated through the femoral vein and internal
jugular/superior vena cava with two cannulas, or a single
dual-lumen cannula placed into the right atrium and in-
ferior vena cava via the right internal jugular vein (Fig. 1).
Venous blood is drained from the vena cava regardless
of the cannulation configuration. After passing through
the oxygenator, blood is returned to the right atrium via
the return cannula (Fig. 2). This configuration requires
blood to pass through the pulmonary circulation and is
systemically circulated by the native cardiac output. Thus,
VV ECMO provides no cardiac support.Fig. 1 Veno-venous cannulation for ARDS. This chest X-ray
demonstrates severe airspace disease in a patient with ARDS.
The dual-lumen ECMO cannula (arrows) can be seen passing through
the internal jugular vein, superior vena cava, and terminating in the
inferior vena cava at the level of the hepatic veinPercutaneous VA ECMO in adults most commonly
involves femoral artery and vein cannulation where oxy-
genated blood is returned to the femoral artery and
flows retrograde into the aorta. Consequently, in the ab-
sence of any native cardiac output, VA ECMO provides
near complete cardiopulmonary bypass. In the presence
of native cardiac output, blood flow out of the left ven-
tricle mixes with retrograde ECMO return flow in the
aorta. If there is no intrapulmonary shunt, the native
cardiac output is well oxygenated and this mixing is not
detrimental. However, if the patient’s lungs are failing
(e.g., because of ARDS), blood flow from the native car-
diac output is deoxygenated and competes with retro-
grade flowing oxygenated blood from the ECMO circuit.
These competing flows mix somewhere in the aorta and
can create differential hypoxemia (“North–south” syn-
drome) whereby poorly oxygenated blood preferentially
perfuses the upper body, including the brain and heart,
potentially leading to coronary and cerebral ischemia.
Contraindications, complications, and ethical
challenges
The decision to use ECMO requires a thoughtful
risk–benefit evaluation. Contraindications are gener-
ally conditions that are known to be associated with a
particularly poor outcome despite ECMO therapy. Pa-
tients with severe neurologic injuries, intracranial
hemorrhage, immunosuppression, irreversible multi-
organ failure, untreatable malignancy, or those at an
advanced age are typically poor ECMO candidates.
Patients with aortic dissections or severe aortic regurgita-
tion are not ECMO candidates due to the risks of propa-
gating the dissection and over-distending the left ventricle,
respectively. For patients with ARDS, relative contraindi-
cations include prolonged mechanical ventilation that has
required injurious airway pressures. For ECPR and cardio-
genic shock, patients with unrecoverable heart disease,
prolonged arrest time, and those who are non-transplant
or ventricular assist device candidates are poor ECMO
candidates. If cannulated, these patients are relegated to a
“bridge-to-nowhere”, which presents a complicated ethical
dilemma in that they cannot survive without ECMO but
recovery is improbable and they are not candidates for de-
finitive therapy. Patients generally require anticoagulation
while on ECMO and, while it is not an absolute contra-
indication, an inability to anticoagulate complicates both
cannulation and long-term management strategies.
Complication rates with ECMO are high. This is true
during both cannulation and ongoing management [69].
Complications include hemorrhage, stroke, limb ischemia,
thrombosis, and infection from the indwelling lines/tubes.
Data show at least one significant complication occurs in
over half of patients on ECMO [65], with bleeding (30–
40 %) [26, 51] and infection (31 %) [51] being the most
Fig. 2 ECMO circuit components and flow. Flow through the ECMO circuit starts with the venous drainage cannula (1), which is propelled
forward by the pressure gradient generated by the centrifugal pump head (2). The blood passes through the oxygenator (3) and then returns to the
patient in the outflow tubing back into the right atrium (VV) or femoral artery (VA) (4). Gas exchange is regulated by the amount of countercurrent
“sweep” gas flowing through the oxygenator (5) and the blood is warmed by the thermoregulator attached to the circuit (6). Flow, hemoglobin,
hematocrit and venous saturation can be continuously monitored by ultrasonic meters attached to the circuit (7 and 8)
Mosier et al. Critical Care  (2015) 19:431 Page 5 of 8common. Hemorrhagic complications most commonly
occur at the cannulation or surgical sites themselves and
are generally related to anti-coagulation, of which VA
ECMO requires more aggressive anticoagulation due to
the risk of arterial thrombosis. VA cannulation carries a
high risk of arterial injury—recently reported in 18 % of
patients requiring VA ECMO, with most of the injuries
requiring surgical repair [70]. Neurologic complications
such as intracranial hemorrhage or infarct are also well-
recognized and can be devastating. Other complications
include hemolysis, pulmonary edema, and lower extremity
ischemia from occlusion of the arterial flow with place-
ment of the arterial cannula, which can be prevented with
the routine placement of an antegrade arterial cannula to
that limb.
Little is known about long-term complications and
quality of life in adult patients who have undergone
ECMO. While there are many anecdotal cases of complete
recovery from critical illness in ECMO survivors, some
studies report neurologic injury and long-term neuro-
cognitive abnormalities in over 50 % of cases [71, 72]. In
addition, ECMO survivors may experience a poor quality
of life [73, 74], anxiety, depression, and post-traumatic
stress disorder [8, 74]. ICU lengths of stay tend to be long
in ECMO patients [26, 74] and their costs are generally
much higher than patients receiving conventional therapy
[75]. The challenges of complications, cost, and resource
utilization, when taken together with the potential of cre-
ating a bridge-to-nowhere situation for some patients andlack of high-quality evidence, create an ethical obligation
to consider the risks and benefits very carefully when con-
sidering ECMO in a patient’s treatment plan.
Conclusion
Since its advent in the 1950s, ECLS has gone from the
operating room to a promising rescue modality for cardio-
pulmonary failure in the ICU and beyond. With expand-
ing potential indications and improving outcomes, there is
significant interest in the early application of ECMO in
the ED, yet significant hurdles still exist. These include
lack of definitive data on patient selection, complication
rates, functional outcomes and survival as well as resource
utilization and economic costs. The H1N1 pandemic,
combined with improvements in general critical care,
brought modern and improved ECMO technology into
the limelight with good outcomes in the treatment of
severe acute respiratory failure. Combined with recent
data in patients with cardiac arrest and shock that show
promising trends, there appears to be potential for the
early application of ECLS to patients in the ED. Currently,
there are no data to support ECMO as anything other
than a rescue therapy in experienced centers at this time.
Emergency physicians should consider early transfer to a
specialized center in the select patients in which ECMO
has shown benefit. Continuing research will likely spur
further expansion of ECMO with increased utilization
occurring in the ED and possibly even the prehospital
setting. However, we encourage a cautious and evidence-
Mosier et al. Critical Care  (2015) 19:431 Page 6 of 8based approach to future applications of ECMO prior to
widespread adoption given the logistical and ethical chal-
lenges of this technology that has the potential to outpace
the supporting data.
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